Opdualag (Nivolumab & Relatimab)
- Drug Name: Opdualag
- Generic Name: Nivolumab & Relatimab
- Dosage Forms and Strengths: Injection: 240 mg of nivolumab and 80 mg of relatlimab per 20 mL in a single-dose vial.
- Manufactured by: Bristol-Myers Squibb
OPDUALAG is a groundbreaking blend of nivolumab, programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody. This innovative combination is specifically indicated for the treatment of adult and pediatric patients, 12 years of age or older, grappling with unresectable or metastatic melanoma.
Recommended Dosage:
- For adult patients and pediatric patients weighing at least 40 kg:
- Administer 480 mg of nivolumab and 160 mg of relatlimab intravenously every 4 weeks.
- Opdualag 480 mg is to be administered as an intravenous infusion over a 30-minute period.
Immune-Mediated Adverse Reactions:
- Various severe or fatal immune-mediated adverse reactions may occur across different organ systems.
- Monitoring for early identification and management is crucial.
- Baseline evaluation of liver enzymes, creatinine, and thyroid function, with periodic assessments during treatment.
- Adjustment or discontinuation based on the severity and nature of the reaction.
- Infusion-related reactions may warrant interruption, slowing of the infusion rate, or permanent discontinuation based on severity.
- Serious complications, including fatal outcomes, are possible in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) before or after receiving treatment with a PD-1/PD-L1 blocking antibody.
- OPDUALAG has the potential to cause fetal harm, and females of reproductive potential should be advised accordingly.
If you are considering the import of Opdualag (Nivolumab & Relatimab) to India, please be aware that Opdualag can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:
Required Documentation for Import:
- A valid prescription from a qualified medical practitioner.
- Diagnostic reports of the patient.
- Government-issued identification proof for the patient, as recognized by the Government of India.
The order for Opdualag will be confirmed upon the receipt of the following documents:
- A valid prescription from a qualified doctor.
- An import permit, if applicable.
Opdualag (Nivolumab & Relatimab) is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.
Opdualag can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.
IPN (Indian Pharma Network) is dedicated to facilitating the supply of Opdualag (prescription medicines) to locations both within India and worldwide while adhering to relevant legal requirements.
Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.
Indian Pharma Network is proficient in sourcing Opdualag (Nivolumab & Relatimab) from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedited prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient’s address, exclusively from New Delhi, India.
Is relatlimab FDA approved?
Relatlimab is the first FDA-approved drug to block the activity of LAG-3. Unlike other FDA-approved combinations of immune checkpoint inhibitors, with Opdualag, patients receive an intravenous infusion containing both drugs.
What is the brand name for Relatelimab and Nivolumab?
Opdualag is a premixed combination of nivolumab and relatlimab that is prepared and given through intravenous (IV) infusions. Opdualag is a prescription medicine used to treat adults who have a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma).
What is the combination of nivolumab and relatlimab?
When used together, nivolumab + relatlimab can treat advanced melanoma more effectively than nivolumab on its own.
What is nivolumab FDA-approved for?
On October 13, 2023, the FDA approved nivolumab (Opdivo, Bristol-Myers Squibb Company) for the adjuvant treatment of completely resected Stage IIB/C melanoma in patients 12 years and older.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.